BackBioNexus Gene Lab Overview

BioNexus Gene Lab Receivables

Track BioNexus Gene Lab's receivables ($170K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$168843.00
↓ 89.94% YoYΔ $-1.51M vs prior year quarter

Peer average

Loading

BioNexus Gene Lab Receivables History

Loading

BioNexus Gene Lab vs. peers: Receivables Comparison

Loading

BioNexus Gene Lab Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

BioNexus Gene Lab (BGLC) FAQ

BioNexus Gene Lab posts a receivables of $170K as of March 2026. That compares with $1.7M in the prior-year period — down 89.9% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, BioNexus Gene Lab's receivables was $1.7M. The latest reading is $170K — a 89.9% year-over-year decrease (period ending March 2026). Use the history and growth charts on this page for a longer lookback.

Receivables is one piece of BioNexus Gene Lab's financial statement story. At $170K, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for BGLC's receivables usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; BioNexus Gene Lab's other metric pages and overview cover the third.